The effect of various concentrations of Aegle marmelos (AME) on the doxorubicin (DOX)-induced genotoxic effects in mice bone marrow was studied. Treatment of mice with different concentrations of DOX resulted in a dose-dependent elevation in the frequency of micronucleated polychromatic (MPCE) as well as normochromatic (MNCE) erythrocytes in mouse bone marrow. The frequencies of MPCE and MNCE increased with scoring time, and the greatest elevation for MPCE was observed at 48 hours post-DOX treatment, whereas a maximum increase in MNCE was observed at 72 hours post-DOX treatment. This increase in MPCE and MNCE was accompanied by a decline in the polychromatic erythrocytes-normochromatic erythrocytes (PCE/NCE) ratio, which showed a DOX-dosedependent decline. Treatment of mice with 200, 250, 300, 350, and 400 mg/kg body weight of AME, orally once daily for 5 consecutive days before DOX treatment, significantly reduced the frequency of DOX-induced micronuclei accompanied by a significant elevation in the PCE/NCE ratio at all scoring times. The greatest protection against DOX-induced genotoxicity was observed at 350 mg/kg AME. The protection against DOX-induced genotoxicity by AME may be due to inhibition of free radicals and increased antioxidant status.
Several drugs are used as chemotherapeutic agents against various forms of human cancers. Genotoxicity of anticancer drugs to normal cells is one of the most undesired consequences of chemotherapy, with the possibility of inducing second malignancies. 1 In an attempt to control neoplastic disorders and distant metastases, the chemotherapeutic agents are administered systemically, which adversely affects normal cells, leading to toxic effects. To combat the adverse physiological effects of these cytotoxic drugs, it is common to prescribe vitamins and/or dietary supplements. Many of these dietary supplements and vitamin combinations contain substantial amounts of antioxidants, free radical-scavenging agents, and general blocking agents. It is presumed that such natural agents have the potential not only to diminish the physiological side effects but also to reduce the genotoxicity of agents. 2 In the recent past, many natural compounds derived from plants and/or their crude extracts have been shown to have a protective effect against the toxic effects of many chemicals. [3] [4] [5] The anthracycline group of antibiotics includes the most effective classes of antineoplastic agents available for the treatment of human cancers. Among the anthracyclines, doxorubicin (DOX) is an important anticancer agent. It is a valuable component of various chemotherapeutic regimens for breast carcinoma and small-cell lung carcinoma. In metastatic thyroid carcinoma, DOX is probably the best available agent. DOX is also an important agent for the successful treatment of Hodgkin disease and non-Hodgkin lymphomas. 6 A clear dose-response relation for DOX in several curative regimens has been shown, and decreased doses result in inferior survival rates, 7 whereas an increase in DOX dose is limited because of severe cardiotoxicity, a major problem in the clinical application of DOX.
There is a large body of evidence to show that the dominant cellular target of DOX is DNA. 8 The anthracyclines are classified as topoisomerase II inhibitors because they effectively stabilize the cleavage complex of topoisomerase II. The antitumor activity of anthracyclines is consistent with their ability to interact with cellular DNA, and this noncovalent interaction can inhibit the function of DNA ligases, helicases, and other DNA-dependent proteins, in addition to topoisomerase II. However, their cellular effects are by no means limited to this type of enzymatic inhibition. DOX exhibits a wide range of cellular effects, and it is likely that no single mechanism of action will account for all of the observed clinical and cellular responses. 8, 9 DOX forms a stable complex with ferric iron, which reacts with oxygen, forming superoxide anions, hydrogen peroxide, and hydroxyl radicals. DOX is known to cause single-strand DNA breaks, chromosomal rearrangements, and mutational events, and it is a potent carcinogen. 10 DOX has been reported to induce micronuclei, chromatid, and chromosome aberrations: DNA single-and double-strand breaks in vitro and in vivo. [11] [12] [13] [14] [15] [16] [17] [18] [19] Until more selective anticancer agents are developed, the sensitivity of normal tissues, such as bone marrow, limits the maximum tolerated doses. Thus, strategies to prevent myelosuppression resulting from chemotherapy are a high priority of research. The micronucleus assay is the most extensively used cytogenetic marker that indicates early biological effects associated with DNA-damaging agents.
Numerous chemical mutagens cause structural chromosomal aberrations, and a proportion of these aberrations (usually referred to as "asymmetrical events" or "unstable aberrations") give rise to chromosome fragments without spindle attachment organelles (kinetochores, centromeres) and are termed acentric fragments. 20, 21 When the cell divides, some of these fragments are excluded from the main daughter nuclei and form small extra nuclei within the cytoplasm, either on their own or in conjunction with other fragments, and are termed micronuclei (MN). Not only the acentric fragments but also the whole chromosome that lags behind during the cell division because of a defect in kinetochore or spindle fibers give rise to MN. Such MN can appear in the cytoplasm of either, or both, daughter cells. MN are small, round, spherical chromatin bodies, found in the cytoplasm outside the main nucleus or in the erythrocytes, which resemble the main nucleus of a cell in shape, size structure, and staining properties. 22, 23 The micronucleus assay is used as an effective cytogenetic end point for assessing the chromosomal damage induced by chemical mutagens and carcinogens. [24] [25] [26] The MN formation and the incidence of chromosomal aberrations are highly correlated. 26, 27 Among the various techniques used to detect genetic and genotoxic effects, the micronucleus test is simple, cheap, and less cumbersome and allows convenient and easy application, particularly in genotoxic studies. 26, 28 Plants have formed the basis of sophisticated traditional medicine systems that have been in existence for thousands of years in countries such as India and China. The use of plants in traditional medicinal systems of many other cultures has been well documented. Plants, by virtue of their wide usage in traditional medicine and low toxicity, have been drawing the attention of researchers around the world in the recent past. Dietary ingredients may be very useful if they are found to protect against the deleterious effects of these antineoplastic agents on the normal tissues, as they will be widely acceptable, would not put an extra foreign substance into the body, and can be safely manipulated without toxic manifestations.
Aegle marmelos (L) Correa, commonly known as bael, is a spinous tree belonging to family Rutaceae. The tree is also called Shivadume, the tree of Lord Shiva. Its edible fruit, leaf, root, bark, and seed are also valued in Ayurvedic medicine in India. 29 In fact, as per Charaka (1500 BC), no drug has been longer or better known or appreciated by the inhabitants of India than the bael. 30 A marmelos has an important place in indigenous systems of medicine. With respect to clinical applications, the unripe fruits are bitter, acrid, sour, astringent, aid digestion and stomach irritation, and useful in treating diarrhea, dysentery, and stomachalgia. 31 Bael has been used traditionally in the Ayurvedic system of medicine as a cardiotonic for treatment of heart ailments. 32, 33 Its common usage, wide acceptability to humans, and diverse medicinal and antioxidative properties stimulated us to study the chemoprotective effect of bael against the doxorubicininduced genotoxicity in mice bone marrow.
Materials and Methods

Chemicals
Doxorubicin hydrochloride (adriamycin) was obtained from the Biochem Pharmaceutical Industries (Mumbai, India). Fetal calf serum (FCS), acridine orange, and Dulbecco's modified Eagle's medium (DMEM) was procured from Sigma Chemical Company (St Louis, Mo).
Animal Care and Handling
Animal care and handling were carried out according to the guidelines issued by the World Health Organization (Geneva, Switzerland) and the Indian National Science Academy (New Delhi, India). Tento 12-week-old male Swiss albino mice weighing 30 to 36 g were selected from an inbred colony maintained under controlled conditions of temperature (23°C ± 2°), humidity (50% ± 5%), and light (12 hours of light and dark, respectively). The animals had free access to sterile food and water. Four animals were housed in a polypropylene cage containing sterile paddy husk (procured locally) as bedding throughout the experiment. The study was approved by the Institutional Animal Ethical Committee of the Kasturba Medical College, Manipal, India.
Preparation of the Drug Solution
A marmelos was identified by Dr Gopal Krishna Bhat (a well-known taxonomist of this area), Department of Botany, Poorna Prajna College, Udupi, India. Mature leaves of the A marmelos tree were collected locally during January to February of the year, cleaned, shade dried, powdered, and extracted. 34 Briefly, 100 g of the leaf powder was extracted with 50% ethanol at 50°C to 60°C in a Soxhlet apparatus for 72 hours. The cooled extract was concentrated to dryness in a lyophilizer. A 24% yield of the extract was obtained. The extract was stored in a freezer at -70°C until use. Henceforth, the extract of A marmelos will be called AME.
Mode of Administration
AME or DOX was dissolved in double-distilled water (DDW) immediately before use. The animals were administered 0.01 mL/g body weight of DDW or AME orally once daily for 5 consecutive days using an oral feeding needle (Popper & Sons Inc, New York, NY) before exposure. 35 
Experimental
Male Swiss albino mice were divided into the following groups.
• AME group: The animals of this group were administered orally with 0, 200, 250, 300, 350, or 400 mg/kg body weight of AME once daily for 5 consecutive days. • DOX group: The animals of this group received doubledistilled water orally, once daily for 5 consecutive days. One hour after the last administration of DDW, animals of this group received a single intraperitoneal injection of 0, 5, 10, or 15 mg/kg body weight DOX. • AME + DOX group: The animals of this group were administered orally 200, 250, 300, 350, or 400 mg/kg body weight of AME once daily for 5 consecutive days. One hour after the last administration of AME, the animals of this group were injected intraperitoneally with a single dose of 5, 10, or 15 mg/kg body weight DOX.
Four animals were used for each dose of AME or DOX in each group for each assay time, and a total of 384 animals were used for the whole experiment.
Micronucleus Assay
The animals from all the above groups were killed by cervical dislocation at 12, 24, 48, or 72 hours after DOX treatment of micronucleus assay. The MN were prepared according to the method of Schmid, 28 with certain modifications described by Jagetia. 36 Briefly, the femurs of each animal were dissected out, and the bone marrow was flushed out into DMEM separately. The cells were pelleted by centrifugation. A few drops of FCS were added, and the pellet was mixed thoroughly. Smears were drawn onto precleaned coded slides using a drop of the resultant suspension in FCS. The slides were air dried and fixed in absolute methanol. The slides were stained with 0.125% acridine orange in Sorensen's buffer (pH 6.8) and washed twice in Sorensen's buffer. The buffer-mounted slides were observed under a fluorescence microscope (Photomicroscope III; Carl Zeiss, Ober Kochen, Germany) using a 40× Neofluar objective. A minimum of 1000 each polychromatic erythrocytes (PCE) and normochromatic erythrocytes (NCE) were screened for the presence of MN for each animal for each dose of DOX or AME.
A total of 4000 each PCE or NCE was scored for each dose of AME as well as DOX for each group. Data regarding the polychromatic and normochromatic erythrocyte ratio (PCE/NCE ratio) were also collected, in which a minimum of 4000 erythrocytes per animal were scored. The protection factor was calculated by combining micronucleated polychromatic erythrocyte (MPCE) and micronucleated normochromatic erythrocyte (MNCE) frequencies for each DOX dose at each scoring time as follows:
DOX-Control
AME+DOX-AME
Statistical Analysis
The statistical significance among the treatments was determined using 1-way analysis of variance. Bonferroni post hoc test was applied for multiple comparisons, wherever necessary. The data were fitted onto linear (Y = α + βD) or linear quadratic (Y = C + αD + βD 2 ) equations to describe the dose response, if any, where C is control MN frequency, D is DOX dose, and α and β are constants.
Results
The results are expressed as MPCE or MNCE per 1000 ± SEM and PCE/NCE ratio ± SEM.
Administration of various doses of AME alone did not alter the spontaneous frequency of MPCE significantly. DOX treatment caused a significant but dosedependent elevation in the MPCE frequency at all postscoring times studied, and a maximum frequency of MPCE was observed for 15 mg/kg DOX. PF = Treatment of mice with 15 mg/kg DOX not only induced MPCE bearing 1 micronuclei but also MPCE bearing multiple MN at all posttreatment times. The frequency of MPCE also showed a timedependent elevation up to 48 hours posttreatment, in which the highest number of MPCEs was scored followed by an abrupt decline thereafter ( Table 1) . The pattern of increase in MPCE in the AME + DOX group was identical to that of the group treated with DOX alone except that treatment of mice with 200, 250, 300, 350, or 400 mg/kg body weight AME before administration of various doses of DOX caused a significant but AME-dose-dependent reduction in the frequency of MPCE depending on the scoring time until 350 mg/kg AME. Thereafter, a marginal elevation was observed, although the frequency of MPCE was still lower than DOX treatment alone at all post-DOX scoring times ( Table 1 ). The greatest reduction in MPCE was observed for 350 mg/kg AME. The protection factor depended on the dose of AME, and the highest protection factor of 3 was observed for 350 mg/kg AME for all doses of DOX except 5 mg, in which it was almost 6 at 48 hours posttreatment ( Table 2 ). The frequency of PCE bearing multiple MN also revealed a DOX-dose-dependent elevation at all post-DOX treatment times, whereas AME treatment reduced the frequency of DOX-induced multiple MN in an AME-dose-dependent manner up to 350 mg/kg (Table 1) . AME treatment alone did not alter the spontaneous frequency of MNCE significantly when compared with the non-drug-treated control ( Table 3 ). The mice treated with different doses of DOX showed a dosedependent elevation in MNCE at all the scoring times, and a maximum number of MNCE was scored for 15 mg/kg DOX. Similarly, the frequency of MNCE increased steadily with scoring time, and the highest frequency of MNCE was observed at 72 hours post-DOX treatment. The MNCE elevation in the AME + DOX group showed a pattern similar to that of the DOX group except that administration of various doses of AME once daily for 5 consecutive days before DOX treatment resulted in an AME-dose-dependent decline in the MNCE at all the scoring times. The frequency of NCE bearing multiple MN also revealed a DOX-dose-dependent elevation at all post-DOX treatment times, whereas AME treatment reduced the frequency of DOX-induced multiple MN in an AMEdose-dependent manner up to 350 mg/kg (Table 3) . A maximum reduction in the number of MNCE was observed in the animals receiving 350 mg/kg AME once daily for 5 consecutive days before treatment with different doses of DOX.
Treatment of mice with different doses of AME did not significantly alter the spontaneous levels of the PCE/NCE ratio. Administration of mice with different doses of DOX resulted in a dose-dependent decline in the PCE/NCE ratio, and the highest decline was observed for 15 mg/kg DOX at all posttreatment times (Figure 1a -c). The PCE/NCE ratio continuously declined with scoring time, and a maximum decline was observed at 72 hours post-DOX treatment (Figure 1 ). Treatment of mice with various doses of AME before DOX treatment arrested the DOXinduced decline in the PCE/NCE ratio in an AMEdose-dependent manner, as evident by a significant elevation in the PCE/NCE ratio when compared to DOX treatment alone at all post-DOX treatment times. A maximum rise in the PCE/NCE ratio was observed for 350 mg/kg AME at all doses of DOX at all scoring times ( Figure 1 ). Among all the AME doses studied, 350 mg/kg body weight AME has shown to afford the best chemoprotection.
Discussion
Genotoxicity of anticancer drugs is of special interest because of the risk of inducing secondary malignancies. Patients undergoing treatment with chemotherapeutic agents for multiple myeloma, Hodgkin disease, and ovarian tumors are at risk for development of secondary tumors after completing the treatment. [37] [38] [39] The use of cytoprotective agents represents an alternative method for reducing radiotherapeutic and chemotherapeutic toxicity in normal tissues, 40 thus preventing the risk of potentially genotoxic effects such as secondary tumor formation. 39 For those agents whose maximum tolerated dose is limited primarily by myelosuppression, several strategies are under evaluation to permit dose escalation in the hope of obtaining better clinical results with currently available chemotherapeutic drugs.
The major acute toxicity induced by DOX is bone marrow suppression, and the long-term clinical usefulness is limited by a cumulative dose-dependent irreversible chronic cardiotoxicity, which manifests itself as congestive heart failure or cardiomyopathy. 41, 42 Therefore, it is essential to screen newer pharmacological agents that can protect the normal cells against DOX-induced cumulative toxicity. Plants, by virtue of their wide usage in traditional medicine, are less toxic and have attracted the attention of researchers around the world in the recent past. Plants contain many compounds, and it is likely that these can provide better protective effects than a single molecule. 43 The presence of many molecules in plants may be advantageous, as some of them may counteract the toxicity of others, and as a result, the net effect may be beneficial for therapeutic purposes.
Topoisomerase II plays an important role in the segregation of newly replicated parts of intertwined DNA strands are rejoined after completion of the above process. 48 The most readily detectable genotoxic effect of topoisomerase interactive agents in somatic cells is the formation of a ternary complex consisting of drug, thus stabilizing the DNA double-strand breaks. 49 DOX is a potent DNA topoisomerase II inhibitor, and it stabilizes DNA double-strand breaks and does not allow them to rejoin, leading to cell death. [50] [51] [52] These DNA double-strand breaks may subsequently lead to chromosomal breaks that finally may lead to the production of MN, with subsequent cell division. 53 The persistence of DNA lesions in DOX-treated cells has been confirmed by MN assay. Micronucleus incidence showed a dose response in large-scale screening for suspected clastogens. 26 DOX treatment resulted in an increased MN frequency in a dose-dependent manner in mouse bone marrow at all post-DOX treatment times. DOX treatment has been shown to increase the frequency of MN in mice bone marrow and human lymphocytes. 12, 54 Reports regarding the reduction in DOXinduced MN by AME are unavailable, and this is probably the first report in which AME pretreatment has been found to reduce DOX-induced MN in vivo. However, earlier studies have shown that AME pretreatment reduces the frequency of radiation-induced MN in cultured human peripheral blood lymphocytes as well as radiation-induced MN in mice bone marrow cells, 55, 56 indicating that it does not exert a genotoxic effect in the dose range studied.
The yield of MN depends on the frequency of the induction of chromosomal fragments, their probability of exclusion at mitosis, proliferation status of cell population, cell cycle delay, and longevity of cells containing MN. The abrupt decline in MPCE frequency at 72 hours post-DOX treatment may be due to the fact that MN are formed in erythroblasts during mitosis. Erythropoiesis is an ongoing process, and there is a continual progression of cells from erythroblasts through the PCE stage to NCE. A considerable fraction of MPCE migrate to the peripheral blood soon after their formation in the bone marrow, before maturing into NCE. Some of the PCE do mature into NCE in the bone marrow itself and then migrate to the peripheral blood. Hence, the sudden decline in MPCE at 72 hours post-DOX treatment may be due to the release of these cells into the bloodstream, as well as dilution of MN with successive cell division, removal of damaged cells, and dilution of the existing cells with the newly formed cells.
The acentric fragments give rise to MN with an efficiency of about 80%, 54 and this apparent saturation of the micronucleus yield is due to the fact that after cell division, the acentric fragment is likely to produce a micronuclei in only 1 of the 2 daughter cells and not because of low efficiency of MN formation. This fact alone will reduce the frequency of MN by a factor of 2 for each cell division, and there is also the possibility of incorporation of more than 1 fragment during the formation of MN. The frequency of MNCE started increasing from 12 hours onward and reached a peak level at 72 hours post-DOX treatment at all the exposure doses. A higher incidence of MNCE indicates that the erythropoiesis was damaged after the S-phase. AME alone did not induce significant MN at all assay times. AME treatment has caused a significant reduction in the MPCE and MNCE frequency in mice exposed to various concentrations of DOX at all assay times studied. Other chemicals such as captopril and desferrioxamine have also been reported to reduce DOX-induced MN in mice. 12, 13 β-carotene and vitamins A, C, and E have also been reported to reduce the incidence of DOX-induced genotoxicty. [57] [58] [59] Several other chemicals such as thiol N-acetylcysteine, probucol, lovastatin, and hydrophilic flavonoids such as rutin and luteolin have been reported to reduce DOXinduced toxicity. [60] [61] [62] [63] DOX caused a dose-dependent decline in the PCE/NCE ratio, indicating its ability to inhibit cell proliferation. The PCE/NCE ratio decreased with time, and the highest decline was observed at 72 hours post-DOX treatment at all the DOX exposure doses. The PCE/NCE ratio is an indicator of the acceleration or inhibition of erythropoiesis. The PCE/NCE ratio has been reported to vary with scoring time, and the continuous decline in the PCE/NCE ratio may be due to the inhibition of cell division, killing of erythroblast, removal of damaged cells, and/or dilution of the existing cell pool with newly formed cells. An identical effect has been observed earlier with DOX and the other topoisomerase II inhibitors VM-26 and etoposide. 12,64,65 AME pretreatment inhibited the decline in PCE/NCE ratio, and the greatest effect was observed for 350 mg/kg AME. A similar effect has been reported earlier, in which captopril has been reported to inhibit the DOX-induced PCE/NCE ratio in mouse bone marrow. 12 Several mechanisms may have been responsible for the cytotoxicity of DOX and micronucleus induction, 66 including intercalation of DOX into cellular DNA, 67,68 stabilization of the topoisomerase II-DNA complex, 69,70 free radical-mediated toxicity caused by redox cycling of the semiquinone radical, 71 or formation of reactive oxygen species by the DOX iron complex. 8, 72, 73 DOX has been reported to be metabolically activated to a free radical state and interacts with molecular oxygen to generate superoxide radicals. 74, 75 The superoxide radicals can react with hydrogen peroxide to form highly reactive hydroxyl radicals via the iron-catalyzed Haber-Weiss reaction. Secondarily derived hydroxyl radicals can cause protein and DNA damage and initiate lipid peroxidation. 76 The production of OH • free radicals and lipid peroxidation may have been responsible for the induction of MN and subsequent decline in the PCE/NCE ratio in the present study.
Iron chelators, catalase, and superoxide dismutase were earlier reported to protect against DOX-induced cell inhibition in MCF-7 and Ehrlich tumor cells. 77, 78 Likewise, nitroxides, superoxide dismutase, and glutathione peroxidase mimetic to protect against DOXinduced toxicity have been demonstrated in various cardiomyocyte models. 73, 79 These above examples support the concept that DOX-mediated free radical production contributes to 1 of the major mechanisms for cytotoxicity.
The results obtained in the present study indicate that AME is capable of imparting protection against DOX-induced clastogenicity, as evidenced by the reduction in the MPCE and MNCE frequency. However, it is worthwhile to mention that some of the components such as flavonoids, rutin, and eugenols, which are constituents of AME, may possibly have played an important role in modulating the in vivo clastogenicity of DOX. The chemoprotection of AME may be due to the presence of aegeline, aegelenine, marmelosine, marmelin/marmesinin, eugenol, linoleic acid, rutin, cineole, p-cymene, citronella, citral, cuminaldehyde, D-limonene, tannins-like ellagic acid and gallic acid, phlobatannins, flavon-3-ols, leucoanthocyanins, anthocyanins, and flavonoid glycoside. 32 Most of these compounds have been reported to possess antioxidant and free radical-scavenging activities. 80 Eugenol has been reported to protect against mutagenicity of cyclophosphamide, mitomycin, and benzo[A]pyrene in mouse bone marrow MN. 81 Similarly, ascorbic acid, a powerful reducing agent, was found to protect against cyclophosphamide-induced clastogenic effects in mice. 82 Flavonoids are polyphenol compounds ubiquitous in plants. Flavonoids are considered protective agents since several reports have discussed their antimutagenic and anticarcinogenic properties. 83 AME has been reported to contain βsitosterol β-D-glucoside, which may have played a role in protection against DOX-induced genotoxicity.
The exact mechanism by which AME protected DOX-induced genotoxicity is not known; however, it may be due to scavenging of DOX-induced free radicals. In our earlier studies, AME has been reported to scavenge free radicals in vitro. 55 Bael may have also inhibited DOX-induced reactive oxygen species generation and thus reduced the damage to cellular DNA. AME has been reported to inhibit reactive oxygen species generation and increase the antioxidant status. 35, [84] [85] [86] Marmesinin, the furanocoumarin present in AME, has been reported to inhibit the DNA adduct formation in vivo. A similar action cannot be ruled out in the present study. 87 The observed chemoprotective effect of AME may be due to the sum total of interaction between different ingredients of this complex mixture. The degree of protection will depend on the interaction of components singly or collectively with the genotoxic agent. Proponents of herbal medicine always claim that mixtures are better than pure chemicals because dozens of biologically active compounds in plants work together to produce a greater effect than any 1 chemical on its own. 88 The plausible mechanisms of action of AME in protecting against DOXinduced genomic insult are scavenging of O 2
•and • OH and other free radicals, increase in antioxidant status, restoration of topoisomerase II activity, and inhibition of the formation of DOX-iron complex. The development of chemoprotectors is dependent on several factors. First, preclinical studies must show that compounds under development are in vivo chemoprotectors. Second, the compounds must be associated with acceptable toxicity in preclinical studies at the doses that are required for chemoprotection. Third, some therapeutic gain must be associated with the administration of the compound by giving differential protection to normal tissues when compared to tumor. Our study is the first step toward the development of a chemoprotective agent from AME that satisfies the first 2 criteria. AME provided protection against DOX-induced genotoxicity in an in vivo system, and the optimum protective dose of 350 mg/kg orally (nontoxic up to 6 g/kg) was devoid of any toxic side effects. AME does not affect the normal cells at the doses that are cytotoxic to neoplastic cells in mice bearing Ehrlich ascites carcinoma, in which an AME dose of 400 mg/kg intraperitoneally was found to be cytotoxic. 89 This property may give a therapeutic gain in clinical situations, as the AME may selectively kill the neoplastic cells while sparing the normal cells. This could be made possible by protection of normal cells by AME and lack of such effect on the tumor tissue. The mechanism by which AME may protect normal versus tumor tissue from the toxicity of chemotherapy is based on several factors, such as physiological differences between the 2 tissue types, resulting in the differential uptake of AME in normal versus tumor tissue. This may cause varied drug distribution into normal and tumor tissues. AME levels may reach higher levels in normal tissues than cancerous tissue because of relatively poorer tumor vascularity. Specific protection of normal tissue represents a promising approach to improve chemotherapy. The ultimate feature of a normal tissue-selective protector is that tumor tissue is excluded from protection. The possibility of tumor protection may not be ruled out completely, and there is a need for emphasis on further research in this area for efficient cancer therapy. Additional studies are being planned to explore whether AME is selectively cytotoxic to neoplastic cells and also to observe differential protection with suitable in vitro and in vivo models. The present study demonstrates that use of AME with DOX may be good paradigm for cancer therapy since AME reduces the genotoxicity of DOX-induced DNA damage.
